Bo Feng

US Patent:

7378388, May 27, 2008

Filed:

Oct 5, 2005

Appl. No.:

11/243619

Inventors:

David B. Seifer - Holmdel NJ, US
Robert Shelden - Kendall Park NJ, US
Bo Feng - Edison NJ, US
Cheryl Dreyfus - Short Hills NJ, US

Assignee:

University of Medicine and Dentistry of New Jersey - Somerset NJ

International Classification:

A01N 37/00
A61K 38/00

US Classification:

514 2, 514 7, 514 8, 514 12

Abstract:

Methods and kits are provided for manipulating and predicting the reproductive capacity of a female subject. The presence of endogenous neurotrophins and addition of exogenous neurotrophins, particularly BDNF, NT-4/5, and NGF, increase the reproductive capacity of a female patient by binding to receptors on the oocytes and stimulating maturation of the oocytes. Administration of antagonists act as a contraceptive because the antagonists prevent the neurotrophins from binding to oocyte receptors. Neurotrophins may also be used to stimulate the maturation of oocyte in vitro.

US Patent:

20030049244, Mar 13, 2003

Filed:

Jul 31, 2002

Appl. No.:

10/209779

Inventors:

David Seifer - Holmdel NJ, US
Robert Shelden - Kendall Park NJ, US
Bo Feng - Edison NJ, US
Cheryl Dreyfus - Short Hills NJ, US

International Classification:

A61K038/43
A61K038/18

US Classification:

424/094100, 514/012000

Abstract:

Methods and kits are provided for manipulating and predicting the reproductive capacity of a female subject. The presence of endogenous neurotrophins and addition of exogenous neurotrophins, particularly BDNF, NT-4/5, and NGF, increase the reproductive capacity of a female patient by binding to receptors on the oocytes and stimulating maturation of the oocytes. Administration of antagonists act as a contraceptive because the antagonists prevent the neurotrophins from binding to oocyte receptors. Neurotrophins may also be used to stimulate the maturation of oocyte in vitro.

US Patent:

20030235878, Dec 25, 2003

Filed:

Apr 30, 2003

Appl. No.:

10/426415

Inventors:

Ira Tabas - New City NY, US
Bo Feng - Teaneck NJ, US

International Classification:

C12Q001/60

US Classification:

435/011000

Abstract:

This invention provides a method for determining whether an agent increases ABCA1-dependent cholesterol efflux from a cell. This invention also provides methods for increasing cholesterol efflux from a cell and for decreasing the amount of cholesterol in a cell. This invention further provides methods for increasing the likelihood that a cholesterol-loaded macrophage will survive and for decreasing the likelihood that a cholesterol-loaded macrophage will contribute to the progression of atherosclerosis. Finally, this invention provides a method for treating a subject afflicted with atherosclerosis, and a related article of manufacture.